NCT03392181View on ClinicalTrials.gov

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

May 1, 2026

Study Completion Date

June 1, 2026

Conditions
Prostate Cancer
Interventions
DRUG

18F-DCFPyL

To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Northwestern University

OTHER